You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.
The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.
Breast cancer risk in carriers of pathogenic CHEK2 variants may be classified as low, moderate, or high by adding in polygenic risk score and family history data.
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
Researchers in Australia are beginning a trial to offer parents-to-be free genetic testing for about 700 conditions, according to the Sydney Morning Herald.
The government-backed project aims to better understand genetic diversity around the South Asian country while helping to inform clinical applications.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
The company is hoping to add outreach to make sure individuals who want counseling get it, and to better understand the reasons why others might not.
The California startup is about to launch its first product, a noninvasive prenatal screening test for recessive single-gene disorders called Unity.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.